07:43 AM EST, 11/13/2025 (MT Newswires) -- HLS Therapeutics ( HLTRF ) said Thursday that third-quarter net loss narrowed slightly as revenue rose.

Net loss improved to US$3.92 million, or $0.12 per share, from a loss of $4.84 million, or $0.15 per share in the prior year period.

Revenue decreased 4% to $13.5 million, primarily due to lower Clozaril Canada revenue, lower royalty revenues and FX rate fluctuations, a statement said.

"Our U.S. Clozaril business has outperformed expectations, but, in addition to FX impacts, our Canadian business has faced headwinds in 2025 that have impacted sales performance," said chief executive Craig Millian.

While Vascepa prescriptions have grown 24% year-to-date, achieving its highest level of profitability this quarter, prescription growth fell short of targets, due to the sales force transition in the first half, Millian added.

The company is expecting bempedoic acid, which lowers LDL cholesterol, to be approved this month, and it will be launching the therapy in the first half of next year.

HLS also updated its fiscal 2025 revenue target to $55 million to $56 million.